IQVIA Holdings Inc. $IQV Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 54.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,206 shares of the medical research company’s stock after selling 8,552 shares during the period. Quantbot Technologies LP’s holdings in IQVIA were worth $1,136,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Verdence Capital Advisors LLC acquired a new position in shares of IQVIA during the second quarter worth about $3,612,000. Act Two Investors LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $26,528,000. Patton Fund Management Inc. acquired a new position in IQVIA during the 2nd quarter worth approximately $231,000. Shell Asset Management Co. boosted its holdings in IQVIA by 78.7% in the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock worth $1,459,000 after acquiring an additional 4,077 shares during the period. Finally, Heritage Investors Management Corp grew its position in IQVIA by 10.5% in the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after acquiring an additional 9,909 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 1.0%

NYSE:IQV opened at $223.66 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market capitalization of $38.09 billion, a price-to-earnings ratio of 30.68, a price-to-earnings-growth ratio of 2.53 and a beta of 1.37. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $234.29. The stock has a 50-day simple moving average of $215.33 and a 200 day simple moving average of $187.66.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IQV. BMO Capital Markets began coverage on shares of IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. UBS Group lifted their target price on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and raised their price objective for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $241.44.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.